Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HFT-012
- Development stage
- Preclinical
- Lead developer
- HemaFlo Therapeutics
- Modality
- Peptides
01
Overview
HFT-012 is a preclinical drag-reducing polymer–based synthetic peptide being developed by HemaFlo Therapeutics for the treatment of acute and chronic renal injury and related urogenital diseases. Public information indicates that drag-reducing polymers are designed to modify blood rheology by suppressing flow disturbances and flattening velocity profiles in the microvasculature, thereby increasing blood flow through the kidneys and potentially improving renal perfusion and function.[4][7][18] HFT-012 remains in early-stage development with no disclosed clinical trial data, approvals, or detailed target-level pharmacology.
Beyond the preview
Go deeper on HFT-012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HFT-012.